How long does it take to lose weight on Wegovy?

This guide matters because this is the question our customer support team hears more than any other about Wegovy.

Either someone is about to start and wants to know what to expect, or they are three or four weeks in, nothing much has happened, and they are worried they have wasted their money.

The reason there is no single answer is that Wegovy does not work at a steady rate.

The first month is slow by design.

Weight comes off fastest through roughly 3-9 months.

It then levels off at around a year, which is later than most people assume when they start.

None of that predicts your own weight loss result with Wegovy.

How much weight you lose, and how quickly, varies a great deal from person to person, and nobody can tell you in advance where you will end up.

What the trial evidence can tell you is whether what you are seeing is normal.

Before you begin: A little bit about OnlineClinic

OnlineClinic has been operating since 2011 and has treated more than 2.1 million patients.

The pharmacy is registered with the General Pharmaceutical Council (GPhC), our prescribers are registered with the General Medical Council (GMC), and the service is regulated by the Care Quality Commission (CQC).

As of August 2026, on Trustpilot, the service rating is 4.6 out of 5 based on 6,491 reviews.

It really helps to understand the small changes you might notice on a routine basis once you start Wegovy.

The timeline, which works in sync with the Wegovy dosage schedule, will give you an idea of what happens to your body once you take your dose.

The once-daily Wegovy pill runs on a different and slightly shorter ladder, covered in its own section below.

Individual experiences vary from person to person.

The 0.25mg Wegovy starter dose is not a treatment dose.

Its job is to let your digestive system get used to semaglutide (the active ingredient in Wegovy) before the amount goes up.

The Wegovy SmPC clearly states that the dose is escalated over 16 weeks, specifically to reduce the likelihood of gastrointestinal side effects.

This is where most of the unnecessary worry sits.

Four weeks feels like a long time when you have been thinking about starting for months, and a flat set of scales at the end of it feels like bad news. It usually isn't.

What people tend to notice in this first month is not weight loss but appetite loss.

Feeling full earlier than usual. Losing interest in a second helping. The background pull towards snacks getting quieter.

On the scales, the picture is mixed.

In the STEP-1 trial, average weight loss was recorded from the first assessment after starting, at week 4, but an average conceals a wide spread.

Losing a kilogram or two in the first month is common. So is losing nothing at all.

From week 5, the dose steps up every four weeks. Four steps, sixteen weeks, and then you are on 2.4mg.

For some people, the ladder has one more rung after that.

0.5mg, weeks 5 to 8

The first dose with a meaningful appetite effect for most people. This is where a lot of our patients see the scales move for the first time.

1mg, weeks 9 to 12

The effect is stronger and steadier. Weekly weight loss tends to become more predictable here rather than arriving in bursts.

1.7mg, weeks 13 to 16

A further step up in appetite suppression. Some people find this dose does enough for them and stay on it long-term with their prescriber's agreement.

2.4mg, week 17 onwards

The first maintenance dose, and the dose on which people usually lose maximum weight. This is where most people spend the bulk of their treatment.

7.2mg, week 21 at the earliest

A second maintenance dose rather than a routine next step.

It exists for people where 2.4mg has not produced enough weight loss, and the licence allows the increase after a minimum of four weeks on 2.4mg.

In practice, the decision usually comes later than week 21, because it depends on what 2.4mg has achieved over a reasonable stretch. More on 7.2mg below.

Reaching 2.4mg is not the finish line, and for a meaningful number of people, it is not the end of the dose schedule either.

It is the point at which the medication is doing what the best-known trials measured, and the phase where the steadiest loss usually happens is the one that follows.

This is the second most common question we get, usually phrased as some version of: I'm tolerating it fine, can I skip a dose?

The answer is no, and the reason is not caution for its own sake.

The MHRA mandates that people taking Wegovy stay on each dose for a minimum of four weeks, so that the body has the time to adjust to each dose.

Moving faster does not produce faster weight loss. It produces more nausea, more vomiting, and more people stopping treatment altogether before they reach a dose that would have worked for them.

The schedule also runs in the other direction. The Wegovy SmPC advises that where gastrointestinal symptoms are significant, escalation can be delayed or the dose reduced to the previous step until things settle.

Our Wegovy side effects week by week guide covers what to expect at each step, and what is worth reporting.

Spending eight weeks on 0.5mg instead of four weeks is a normal clinical decision, not a setback.

Each increase is reviewed by a GMC-registered prescriber before it is issued.

It is normal to be curious about how long it takes to lose weight on Wegovy.

The best way to understand the weight loss timeline on Wegovy is to look at various clinical trials.

Four one-year Wegovy clinical trials look at various dosages and forms of Wegovy and how long they take to produce desirable weight loss for the participants involved.

Wegovy 2.4mg (STEP-1)

Published in the New England Journal of Medicine, 2021. Followed 1,961 adults with overweight or obesity for 68 weeks, including the 16 weeks of dose escalation.

Average weight change at week 68: 14.9% with Wegovy, against 2.4% with placebo. Read the trial

Wegovy 2.4mg (Two-year data: STEP-5)

Published in Nature Medicine, 2022. Followed 304 adults for 104 weeks, the longest randomised follow-up in the programme.

Average weight loss at two years: 15.2% with Wegovy 2.4mg dose, against 2.6% with placebo. Read the trial

Wegovy 7.2mg (STEP UP)

Published in The Lancet Diabetes & Endocrinology, 2025. Followed 1,407 adults with obesity for 72 weeks.

Average weight loss with Wegovy 7.2mg was 20.7%, and average weight loss with Wegovy 2.4mg was 17.5%, against 2.4% with placebo. Read the trial

Wegovy pill 25mg (OASIS 4)

Published in the New England Journal of Medicine, 2025. Followed 307 adults for 64 weeks on the once-daily tablet, which the MHRA licensed for UK weight management in June 2026.

Average weight change at week 64: 13.6% with the tablet, against 2.2% with placebo. Read the trial

The four trials side by side

One caveat: These were separate trials with different participants and different lengths, so the figures are indicative rather than a head-to-head result.

The one fair within-trial comparison is STEP UP, which tested Wegovy 7.2mg and 2.4mg against each other in the same population and found meaningful results.

Comparing the tablet's 13.6% weight loss to the injection's 14.9% weight loss across two different trials tells you they are in similar territory, not that one beats the other.

The practical read. All four trials produce the same picture, and it is easier to see than to describe.

Weight loss is slow for the first month or two, fastest through roughly months three to nine, and then it flattens.

In STEP-1, the average reached its lowest point at week 60, a little over a year in, and STEP-5 showed that weight loss largely held through a second year of treatment.

The useful conclusion is that a year is the sensible horizon for this treatment, whichever form you take it in, not twelve weeks.

Every figure above is an average across thousands of people. Some participants lost far more, some lost very little, and the trials cannot tell you which of those you will be.

You can start Wegovy with OnlineClinic after a free consultation with our GMC-registered prescriber, who will set your starting dose and review each increase as you go.

We are often asked for a weekly weight loss target. We would rather not give one, and there is a good reason for that.

Week-to-week weight loss is noisy.

It moves with fluid, salt, what you ate yesterday, bowel habit, where you are in your menstrual cycle, and whether you have trained recently.

A week showing no weight loss, or a small weight gain, tells you almost nothing on its own.

Weighing yourself more than once a week tends to generate anxiety rather than information. Weighing yourself once a week, same day, same time, similar conditions, is enough.

Over a longer time window, there is a recognised clinical benchmark. NICE's appraisal of semaglutide sets a review point of at least 5% of initial body weight lost after six months of treatment, and advises considering whether to continue if that has not been achieved.

Six months is a long enough time to notice the effects of the escalation phase, plus a real stretch on the maintenance dose, which is why it is a more meaningful checkpoint than any weekly figure.

For someone starting at 100kg, that is 5kg by month six.

The large majority of participants in STEP-1 passed that mark.

It is the point at which a prescriber would want to review your treatment, not a target to aim for.

Comparing yourself to someone else on the same dose is the fastest route to feeling like the medication has failed you, and it is rarely a fair comparison.

The weight loss results in STEP-1 were varied: At the same dose, some participants lost more than a fifth of their body weight, and others lost almost nothing.

The factors that contribute to weight loss include:

• The dose you actually reach. Someone stable on 2.4mg and someone who stopped at 1mg because of side effects are not on comparable treatment.
• Consistency. Missed or late doses interrupt the reduced appetite effect.
• Starting weight. The same percentage is a very different number of kilograms at 90kg and 140kg.
• What you eat and how much you move. Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not as a replacement for them.
• Type 2 diabetes. Average weight loss is lower. In the STEP-2 trial, which enrolled adults with type 2 diabetes, average loss at week 68 was 9.6% against 14.9% in STEP-1.
• Other medications and conditions. Some medicines promote weight gain, and conditions such as PMOS or an underactive thyroid affect the picture.

None of these are reasons to lower your expectations. They are reasons to compare yourself against your own starting point rather than against a friend, a forum post, or a trial average.

Almost everyone hits a stretch where the weight loss slows, and it usually arrives somewhere between month three and month six.

It is easy to read as the medication wearing off. In most cases, it is the curve doing what the curve does.

There is also simple arithmetic at work.

A lighter body burns fewer calories at rest, so the same appetite reduction produces a smaller deficit at 85kg than it did at 100kg.

The distinction worth making is between a slowdown and a genuine stall.

A few weeks of small or no change is a slowdown.

Two to three months of no change at all, while on a stable maintenance dose and taking it consistently, is a weight loss stall, and it is worth discussing with your prescriber.

The mechanism is the same across GLP-1 medications, and our guide to weight-loss plateaus goes through the clinical and practical responses in detail.

If things don’t improve, moving to a different medication is a normal option rather than a last resort.

We cover that in switching from Wegovy to Mounjaro, and the two treatments are compared directly in Mounjaro vs Wegovy.

The 7.2mg dose was approved in the UK in early 2026.

The Wegovy SmPC allows an increase to 7.2mg once weekly after a minimum of four weeks on 2.4mg, where additional weight reduction is clinically warranted for someone with obesity.

In practice, that makes week 21 the earliest possible point, and for most people, it comes later, because the decision depends on how much progress 2.4mg has produced over a reasonable stretch.

It is not an automatic next step, and it is not available on request. Your prescriber decides, based on your response and how well you have tolerated 2.4mg.

In the STEP UP trial, the higher dose added about three percentage points of average weight loss over 72 weeks, 20.7% on 7.2mg against 17.5% on 2.4mg.

Side effects were much like the lower doses: Mostly stomach-related, and mostly while the dose was going up.

Since 11 June 2026, there has been a second way to take Wegovy in the UK.

The MHRA licensed oral semaglutide, widely known as the Wegovy pill, for weight management. It is the first GLP-1 tablet licensed for weight loss in this country.

If you have put off treatment because of the injection, this is the development that matters most to you.

Same active ingredient, once-daily tablet, no needle. It is licensed for the same group of adults as the injection: a BMI of 30 or above, or 27 to 30 with at least one weight-related health condition.

It is not the same thing as Rybelsus, which is a lower-dose oral semaglutide licensed only for type 2 diabetes.

The escalation is slightly shorter

The pill climbs through four doses with a minimum of four weeks at each step, which puts you on the maintenance dose a few weeks earlier than the injection does.

Thirteen weeks against sixteen is not a dramatic difference, and it does not change the broader picture: The trial that led to approval ran for 64 weeks, so a year remains the sensible horizon either way.

How to take the Wegovy pill

The Wegovy pill is swallowed whole, on an empty stomach, with a sip of plain water, after at least eight hours without food.

Then, nothing to eat or drink for another 30 minutes.

So it is a daily routine rather than a weekly one, and it suits some mornings better than others.

Side effects are much the same as with the injection, mostly stomach-related, and mostly while the dose is going up.

You can start the Wegovy pill with OnlineClinic through the same free consultation as the injection.

A GMC-registered prescriber checks that it is suitable for you, sets your starting dose, and reviews each increase as you go.

Contact a doctor or seek urgent medical advice if you have:

• Severe or persistent vomiting, or signs of dehydration such as very little urine output, dizziness on standing, or confusion
• Severe pain in the upper abdomen, particularly if it spreads through to your back, which can be a sign of pancreatitis
• Pain in the upper right abdomen with fever or yellowing of the skin or eyes, which can indicate a gallbladder problem
• Symptoms of low blood sugar, such as shaking, sweating, and confusion, which matters most if you also take insulin or a sulphonylurea along with Wegovy

Get in touch with our prescriber through your account if:

• You have lost less than 5% of your starting weight at six months
• Side effects are not easing after a few weeks at the same dose
• You have missed doses and are unsure how to restart
• You want to discuss changing the dose or treatment

Suspected side effects can also be reported directly through the MHRA Yellow Card scheme.

The consultation is quite straightforward.

1. You fill in a short medical questionnaire. Your weight and height, medical history, current medications, and any previous experience with weight loss treatment.
2. A GMC-registered prescriber reviews it. Usually the same working day. They decide whether Wegovy is suitable and which dose to start at.
3. If approved, it's dispensed and dispatched. From our GPhC-registered pharmacy, packed for temperature-sensitive delivery, with next-day dispatch.
4. If it isn't suitable, the prescriber explains why. They may suggest an alternative. You are not charged for treatment that isn't issued.

Our Wegovy injection and pill prices start from £69.99 and include the prescription, the consultation, packaging, and delivery.

There are no separate fees.

Each dose increase is reviewed before it is issued, so the prescriber sees how you are getting on at every step rather than only at the start.